Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 15/20 | 0.68 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.68 |
| ▸ | MAPK11 | Q15759 | 15/20 | 0.68 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094648 | 1.00 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11TTR | |
| SCHEMBL6095263 | 0.91 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11TTR | |
| SCHEMBL6095267 | 0.91 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11TTR | |
| SCHEMBL6095851 | 0.89 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11TTR | |
| SCHEMBL6095844 | 0.89 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11TTR | |
| SCHEMBL6097674 | 0.88 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11TTR | |
| SCHEMBL6097664 | 0.88 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11TTR | |
| SCHEMBL6097891 | 0.87 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL6097886 | 0.87 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL6096095 | 0.86 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | claimed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | claimed |
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | MAPK14 1972/4885MAPK13 2918/4885MAPK12 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.